| Literature DB >> 31510062 |
Giulia Brunello1,2, Hamada Elsayed3,4, Lisa Biasetto5.
Abstract
The overall success and long-term life of the medical implants are decisively based on the convenient osseointegration at the hosting tissue-implant interface. Therefore, various surface modifications and different coating approaches have been utilized to the implants to enhance the bone formation and speed up the interaction with the surrounding hosting tissues, thereby enabling the successful fixation of implants. In this review, we will briefly present the main metallic implants and discuss their biocompatibility and osseointegration ability depending on their chemical and mechanical properties. In addition, as the main goal of this review, we explore the main properties of bioactive glasses and silica-based ceramics that are used as coating materials for both orthopedic and dental implants. The current review provides an overview of these bioactive coatings, with a particular emphasis on deposition methods, coating adhesion to the substrates and apatite formation ability tested by immersion in Simulated Body Fluid (SBF). In vitro and in vivo performances in terms of biocompatibility, biodegradability and improved osseointegration are examined as well.Entities:
Keywords: bioactive glass; bioactive silicate ceramic; coating; implants; osseointegration
Year: 2019 PMID: 31510062 PMCID: PMC6766230 DOI: 10.3390/ma12182929
Source DB: PubMed Journal: Materials (Basel) ISSN: 1996-1944 Impact factor: 3.623
Figure 1(a) Fracture toughness and density; (b) elastic modulus and density of bone, coating materials and most common metallic materials used in orthopedics and implant dentistry. Data elaborated using CES EduPack™ 2018.
Different metallic materials and their mechanical, thermal and physical properties in comparison to bone. Data from CES EduPack™ 2018.
| Metallic Material | E (GPa) | Hv (GPa) | CTE (10−6K−1) | Tm (°C) | |
|---|---|---|---|---|---|
| CpTi | 100–105 | 1.520–1.618 | 8.5–9.3 | 1670 | 4510–4520 |
| Ti-6Al-4V | 113–115 | 3.256–3.589 * | 8.7–9.1 * | 1610–1660 | 4430 |
| Ti-6Al-7Nb | 100–110 | 2.648–2.844 * | 8–9.8 | 1530–1590 | 4510–4530 |
| Ti-12Mo-6Zr-2Fe | 63.1–90.1 | 3.207–3.383 * | 8.7–8.89 | 1540–1620 * | 4980–5000 |
| 316L SS | 190–205 | 1.667–2.158 | 15–18 | 1380–1400 | 7870–8070 |
| Mg | 44–45.5 | 0.245–0.490 | 25.5–26.5 | 642–650 | 1730–1750 |
| AZ91 Mg alloy | 44–46 | 0.588–0.598 | 26–26.3 | 482–602 | 1800–1810 |
| ZK61 Mg alloy | 44–46 | 0.824–0.892 * | 25–26 * | 470–530 * | 1803–1840 |
| Bone | 17–22 | 0.196–0.392 * | 10–30 * | 110–130 *§ | 1800–2100 |
* Estimated values; § glass Temperature; E = modulus of elasticity; Hv = hardness, Vickers; CTE = coefficient of linear thermal expansion; Tm = melting temperature; ρ = density.
Common bioactive glasses (for example, but not limited) used in medical devices and their composition.
| Commercial Name/Material | Composition (in wt.%) | Composition (in mol%) | References |
|---|---|---|---|
| 45S5 Bioglass | 45% SiO2, | 46.1% SiO2, | [ |
| 24.5% CaO, | 26.9% CaO, | ||
| 24.5% Na2O, | 24.4% Na2O, | ||
| 6.0% P2O5 | 2.6% P2O5 | ||
| S53P4 | 53% SiO2, | 53.8% SiO2, | [ |
| 20% CaO, | 21.9% CaO, | ||
| 23% Na2O, | 22.7% Na2O, | ||
| 4% P2O5 | 1.7% P2O5 | ||
| BG_Ca | 46.9% SiO2, | 47.2% SiO2, | [ |
| 42.3% CaO, | 45.6% CaO, | ||
| 4.7% Na2O, | 4.6% Na2O, | ||
| 6.1% P2O5 | 2.6% P2O5 | ||
| CaK | 46% SiO2, | 47.2% SiO2, | [ |
| 41% CaO, | 45.6% CaO, | ||
| 7% K2O, | 4.6% K2O, | ||
| 6% P2O5 | 2.6% P2O5 | ||
| 13-93 | 53% SiO2, | 54.6% SiO2, | [ |
| 20% CaO, | 22.1% CaO, | ||
| 6% Na2O, | 6% Na2O, | ||
| 4% P2O5, | 1.7% P2O5, | ||
| 12% K2O, | 7.9% K2O, | ||
| 5% MgO | 7.7% MgO | ||
| Sr-Bioglass | 41.5% SiO2, | 44.5% SiO2, | [ |
| 18.7% CaO, | 21.5% CaO, | ||
| 26.2% Na2O, | 27.2% Na2O, | ||
| 9.7% P2O5, | 4.4% P2O5, | ||
| 3.9% SrO | 2.4% SrO | ||
| 70S30C | 71.4% SiO2, | 70% SiO2, | [ |
| 28.6% CaO | 30% CaO | ||
| 58 S | 58% SiO2, | 60% SiO2, | [ |
| 33% CaO, | 36% CaO, | ||
| 9% P2O5 | 4% P2O5 | ||
| 77 S | 77% SiO2, | 80% SiO2, | [ |
| 14% CaO, | 16% CaO, | ||
| 9% P2O5 | 4% P2O5 |
Common silica-based ceramics used in medical devices and their composition, mechanical, thermal and physical properties (dense structure).
| System | Materials | Compositions | CTE (10−6K−1) | E (GPa) | References | |
|---|---|---|---|---|---|---|
|
| Wollastonite | CaSiO3 | 10–13 | 52 | 2900 | [ |
| Dicalcium silicate | Ca2SiO4 | 8.5 | 10–40 | 3150 | [ | |
| Tricalcium silicate | Ca3SiO5 | _ | 24.9–36.7 | 3210 | [ | |
| Dimagnesium silicate | Mg2SiO4 | _ | _ | 3271 | [ | |
| Magnesium silicate | MgSiO3 | _ | _ | 2600–2800 | [ | |
| Zinc silicate | Zn2SiO4 | _ | _ | 3300 | [ | |
| Strontium silicate | SrSiO3 | 10.9 | _ | 3650 | [ | |
|
| Akermanite | Ca2MgSi2O7 | 9.9 | 42–56 | 2961 | [ |
| Bredigite | Ca7MgSi4O16 | _ | 43 | 3400 | [ | |
| Diopside | CaMgSi2O6 | 8.4 | 170 | 3200 | [ | |
| Merwinite | Ca3MgSi2O8 | _ | 31–49 | 3150–3330 | [ | |
| Hardystonite | Ca2ZnSi2O7 | 11.2 | 37 | 3392 | [ | |
| Sphene | CaTiSiO5 | 6 | _ | 3539 | [ | |
| Baghdadite | Ca3ZrSi2O9 | _ | 82–120 | 3480 | [ |
Synthesis and deposition methods of bioactive coatings onto metallic substrates and their average roughness and thickness.
| Substrate | Coating Material | Synthesis Method | Deposition Method | Coating Ra (μm) | Average Coating Thickness (μm) | References |
|---|---|---|---|---|---|---|
| CpTi | Sphene | Polymer-derived ceramics route | Airbrushing | 4.1–6.5 | 50–100 | [ |
| CpTi | Sphene | Polymer-derived ceramics route | Airbrushing | 3.1–8.4 | 133.8 | [ |
| CpTi | Sphene | Polymer-derived ceramics route | Airbrushing | 0.5–1.4 | 120 | [ |
| CpTi | Sphene | Polymer-derived ceramics route | Airbrushing | 3.9 | – | [ |
| Ti-6Al-4V | Sphene | Solid phase reaction | Plasma-spraying | 7.5 | – | [ |
| Hardystonite | Solid phase reaction | Plasma-spraying | 7.5 | – | ||
| Ti | Sphene | Liquid phase reaction | Micro-arc oxidation | – | ≤21 | [ |
| Ti-6Al-4V | Sphene | Sol-gel | Dip-coating | – | – | [ |
| Ti-6Al-4V | Sphene | Sol-gel | Plasma-spraying | 10 | 150 | [ |
| Ti-6Al-4V | Sphene | Sol-gel | Spin-coating | 0.4 | 0.5–1 | [ |
| Ti-6Al-4V | Hardystonite | Sol-gel | Plasma-spraying | 12.1 | 170 | [ |
| Ti-6Al-4V | Hardystonite | Solid phase reaction | Plasma-spraying | 7.7 | 15–18 | [ |
| Sr-substituted hardystonite | Solid phase reaction | Plasma-spraying | 7.2 | 15–18 | ||
| Ti-6Al-4V | Akermanite | Sol-gel | Plasma-spraying | – | 400 | [ |
| Ti-6Al-4V | Baghdadite | Solid state reaction | Plasma-spraying | 9.8 | 120 | [ |
| Ti-6Al-4V | Bredigite | Sol-gel | Plasma-spraying | – | 200 | [ |
| Ti-6Al-4V | Diopside | Commercially available powder | Plasma-spraying | 8.3 | 200–300 | [ |
| Ti-6Al-4V | Dicalcium silicate | – | Plasma-spraying | – | 380 | [ |
| Ti-6Al-4V | Wollastonite | Commercially available powder | Plasma-spraying | – | 350–400 | [ |
| Ti-6Al-4V | Wollastonite | Liquid phase reaction | Atmosphere plasma spraying (+hydrothermal technology) | – | 120–150 | [ |
| Ti-6Al-4V | Wollastonite glass-ceramic | Commercially available powder | Thermal spraying | 9 | 100–150 | [ |
| Wollastonite (36.77 in wt%)-diopside (63.23 in wt%) glass-ceramic | Commercially available powder (wollastonite); solid state reaction (diopside) | Thermal spraying | 11 | 130–200 | ||
| Ti-6Al-4V | Bioactive glass-ceramic with glass phase (SiO2–Al2O3–CaO–P2O5–CaF2) and with fluorapatite (Ca5(PO4)3F) and diopside | Melting and crystallization | Airbrushing | 0.4–1 | 53 | [ |
| Ti-6Al-4V | Bioactive glass in mol%: | Melting | Plasma-spraying | 11.9 | 50–100 | [ |
| Ti-6Al-4V | BG Ca | Melting | Plasma-spraying | – | 30–40 | [ |
| CpTi | Bioactive glass (in mol%: 2.3 K2O, 2.3 Na2O, 45.6 CaO, 2.6 P2O5, 47.3 SiO2) + HA | Melting | High velocity suspension flame spraying | – | 30 | [ |
| Suspension plasma spraying | – | ≤50 | ||||
| Ti-6Al-4V | CaK | Melting | Pulsed electron deposition | – | 1 | [ |
| 45S5 Bioglass | Melting | Pulsed electron deposition | – | 1 | ||
| CpTi | 45S5 Bioglass | Melting | High velocity suspension flame spraying | – | 41–83 | [ |
| Ti | HA + Bioactive glass S53P4 | Commercially available powder | Radio frequent magnetron sputtering | 1.5–2 | 2–3 | [ |
| Ti | HA + Bioactive glass S53P4 | Commercially available powder | Radio frequent magnetron sputtering | 1.2 | 2.1 | [ |
| Ti-6Al-4V | Bioactive glass in wt.%: | Melting | Vitreous enameling technique | – | 70–100 | [ |
| Ti grade 4 | x CaO·(1−x)SiO2 bioactive glass (0.0 ≤ x ≤ 0.60) | Sol-gel | Dip-coating | – | – | [ |
| Ti grade 4 | 70S30CxA bioactive glass (in mol%: 70 SiO2 (S), 30 CaO (C), x Ag2O (A), | Sol-gel | Dip-coating | – | – | [ |
| 316L SS | Hardystonite | Sol-gel | Electrophoretic deposition | – | 14 | [ |
| 316L SS | Hardystonite | Sol-gel | Electrophoretic deposition | – | – | [ |
| 316L SS | Wollastonite glass-ceramic | Commercially available powder | Thermal spraying | 10 | 100–150 | [ |
| Wollastonite (36.77 in wt.%)-diopside (63.23 in wt.%) glass-ceramic | Commercially available powder (wollastonite); solid state reaction (diopside) | Thermal spraying | 13 | 130–200 | ||
| 316L SS | Hybrid organic-inorganic + wollastonite | Sol-gel | Dip-coating | – | 1.1 | [ |
| 316L SS | Hybrid organic-inorganic + wollastonite | Sol-gel | Dip-coating | – | 1.1 | [ |
| 316L SS | Hybrid organic-inorganic + 45S5 Bioglass | Sol-gel | Dip-coating | – | 4.2 | [ |
| Hybrid organic-inorganic + 45S5 Bioglass with Ca partially substituted with 2mol% of Sr | Sol-gel | Dip-coating | – | 4.2 | ||
| Mg alloy (AZ91) | Diopside + bredigite + fluoridated HA | Sol-gel | Anodic spark deposition + electrophoretic deposition | – | – | [ |
| Mg alloy (AZ91) | Merwinite | Sol-gel | Plasma electrolytic oxidation + electrophoretic deposition | 7 | 250 | [ |
| Mg alloy (AZ91) | Diopside | Sol-gel | Micro-arc oxidation + electrophoretic deposition | – | – | [ |
| Mg alloy (ZK60) | Dimagnesium silicate–Magnesium oxide | Liquid phase reaction | Micro-arc oxidation | – | – | [ |
| Mg alloy (ZK61) | Dimagnesium silicate + Magnesium oxide + Clinoenstatite | Liquid phase reaction | Micro-arc oxidation | – | 10 | [ |
| Mg alloy (AZ31) | 45S5 glass–ceramic | Sol-gel | Dip-coating | – | 1 | [ |
| Mg alloy (AZ31) | 45S5 glass–ceramic | Sol-gel | Dip-coating | – | 0.5–1.0 | [ |
| Mg alloy (AZ31B) | 45S5 glass–ceramic | Sol-gel | Dip-coating | – | – | [ |
| Mg alloy (AZ31) | 45S5 glass–ceramic | Sol-gel | Dip-coating | – | 1.1 | [ |
| Mg-Ca (1.4 wt.%) alloy | RKKP * | Liquid phase reaction | Pulsed laser deposition | – | 100 | [ |
* RKKP: glass-ceramic material, RKKP stands for Ravaglioli A, Krajewski A, Kirsch M, Piancastelli A, a coating material with the following composition (in wt.%): 43.68 SiO2, 24 β-Ca3(PO4)2, 18.40 CaO, 4.92 CaF2, 4.53 Na2O, 2.78 MgO, 0.19 K2O, 1.00 Ta2O5, 0.50 La2O3.
Figure 2SEM micrographs of the cross section of: (a) wollastonite and (b) wollastonite-diopside glass ceramic coatings deposited on Ti-6Al-4V substrate, from Garcia et al., 2018 [146].
Coating-substrate adhesion strength.
| Substrate | Coating Material | Test Performed | Adhesion Strength (MPa) | References |
|---|---|---|---|---|
| CpTi | Sphene | Scratch test | – | [ |
| CpTi | Sphene | Scratch test | – | [ |
| CpTi | Sphene | Scratch test | – | [ |
| Nanoindentation | – | |||
| Ti-6Al-4V | Sphene | ASTM C-633 | 41.0 ± 3.5 | [ |
| Hardystonite | ASTM C-633 | 27.0 ± 3.9 | ||
| Ti-6Al-4V | Sphene | ASTM C-633 | 33.2 ± 2.4 | [ |
| Ti-6Al-4V | Sphene | Scratch test | 17.4 ± 0.9 | [ |
| Ti-6Al-4V | Hardystonite | ASTM C-633 | 33.4 ± 2.2 | [ |
| Ti-6Al-4V | Hardystonite | ASTM C-633 | 27 ± 4 | [ |
| Sr-substituted hardystonite | ASTM C-633 | 35 ± 6 | ||
| Ti-6Al-4V | Akermanite | ASTM C-633 | 38.7–42.2 | [ |
| Ti-6Al-4V | Baghdadite | ASTM C-633 | 28 ± 4 | [ |
| Ti-6Al-4V | Bredigite | ASTM C-633 | 41.1–49.8 | [ |
| Ti-6Al-4V | Diopside | ASTM C-633 | 32.5 ± 2.8 | [ |
| Ti-6Al-4V | Dicalcium silicate | ASTM C-633 | 38.9 ± 3.5 | [ |
| Ti-6Al-4V | Wollastonite | ASTM C-633 | 27.4–42.8 | [ |
| Ti-6Al-4V | Wollastonite glass-ceramic | Microindentation test | – | [ |
| Wollastonite (36.77 in wt.%)-diopsite (63.23 in wt.%) glass-ceramic | Microindentation test | – | ||
| Ti-6Al-4V | Bioactive glass-ceramic with glass phase (SiO2–Al2O3–CaO–P2O5–CaF2) and with fluorapatite and diopside | Scratch test | – | [ |
| Ti-6Al-4V | BG_Ca | Scratch test | – | [ |
| Ti-6Al-4V | CaK | Scratch test | – | [ |
| 45S5 Bioglass | Scratch test | – | ||
| 316L SS | Wollastonite glass-ceramic | Microindentation test | – | [ |
| Wollastonite (36.77 in wt.%)-diopside (63.23 in wt.%) glass-ceramic | Microindentation test | – | ||
| Mg alloy (AZ31B) | 45S5 Glass–ceramic | Tensile adhesion test | 14.2–26.8 | [ |
| Mg alloy (AZ31) | 45S5 Glass–ceramic | Tensile adhesion test | 10.1–27 | [ |
Figure 3Adhesion strength and thickness of bioactive coatings. Data obtained by merging data available in Table 4 and Table 5.
In vitro apatite forming ability of the coatings assessed by immersion SBF.
| Substrate | Coating Material | Control | Soaking Time (days) | Surface Analysis | Ion Release Concentration | Main Results | Reference |
|---|---|---|---|---|---|---|---|
| Ti-6Al-4V | Sphene | – | 21 | SEM, | – | Presence of nanocrystals of apatite on the surface. | [ |
| Ti-6Al-4V | Hardystonite | – | 28 | SEM, | – | After 28 days, two layers were present on the coating surface: | [ |
| Ti-6Al-4V | Akermanite | – | 2, 6, 14 | SEM, | ICP-OES | After two days: some apatite particles on the surface. | [ |
| Ti-6Al-4V | Baghdadite | – | 14, 28 | SEM, | – | Apatite formation already obvious after 14 days of immersion. | [ |
| Ti-6Al-4V | Bredigite | – | 2, 6, 14 | SEM, EDS, FTIR, XRD | ICP-OES | Presence of apatite layer after two days, becoming denser after six days of soaking. | [ |
| Ti-6Al-4V | Diopside | – | 5, 15 | SEM, | – | After five days: isolated granular crystals composed of calcium and phosphorous. | [ |
| Ti-6Al-4V | Dicalcium silicate | – | 2, 7, 14, 21 | SEM, | ICP-AES | After two days: a carbonate-containing HA layer was formed on the surface of coating, with the presence of an intermediate silica-rich layer. | [ |
| Ti-6Al-4V | Wollastonite | Calcium silicate coating (without HT) | 1, 3, 7 | SEM, | _ | HT at 180 °C for 24 h enhanced apatite-mineralization ability of the coatings. | [ |
| Ti-6Al-4V | Wollastonite glass-ceramic | _ | 7, 14 | SEM, | ICP-AES | Wollastonite glass-ceramic coating exhibited significantly higher dissolution rate than wollatonite-diopsite glass-ceramic coating. | [ |
| Wollastonite (36.77 in wt%)-diopside (63.23 in wt%) glass-ceramic | |||||||
| Ti-6Al-4V | Bioactive glass-ceramic with glass phase (SiO2–Al2O3–CaO–P2O5–CaF2) and with fluorapatite and diopside | _ | 7, 14, 21 | SEM, | _ | Formation of fluorapatite layer onto the coating surface. | [ |
| Ti-6Al-4V | BG Ca | – | 1, 3, 7, 14 | SEM, | – | All the coatings developed a surface layer of hydroxy-carbonated-apatite. | [ |
| CpTi | Bioactive glass (in mol%: 2.3 K2O, 2.3 Na2O, 45.6 CaO, 2.6 P2O5, 47.3 SiO2) + HA | HA | 1, 3, 7, 14 | SEM, | _ | Porous SPS bioactive glass coatings more rapidly dissolved in SBF, as compared to HVSFS bioactive glass coatings. | [ |
| CpTi | 45S5 bioglass | Bulk glass | 1, 3, 7, 14, 28 | SEM, | ICP-OES | After one-day presence of HA layer on the sample surface. | [ |
| Ti grade 4 | xCaO·(1−x)SiO2 bioactive glass (0.0 ≤ x ≤ 0.60) | Uncoated | 7, 21 | SEM, | – | After seven days: uncoated samples showed fewer bone-like apatite globular grains in comparison to coated samples. | [ |
| Ti grade 4 | 70S30CxA bioactive glass (in mol%: 70 SiO2 (S), 30 CaO (C), x Ag2O (A), with 0.08 ≤ x ≤ 0.27) | Uncoated | 21 | SEM, | – | Coated samples showed the surface covered by apatite globular crystals. | [ |
| 316L SS | Hardystonite | – | 3, 7, 14 | SEM, | – | After three days: no changes in coating morphology. | [ |
| 316L SS | Wollastonite glass-ceramic | – | 7, 14 | SEM, | ICP-AES | Wollastonite glass-ceramic coating exhibited significantly higher dissolution rate than wollatonite-diopsite glass-ceramic coating. | [ |
| Wollastonite (36.77% in wt.%)-diopside (63.23% in wt.%) glass-ceramic | |||||||
| 316L SS | Hybrid organic-inorganic + wollastonite | – | 5, 33 | SEM, | – | An apatite-like layer was observed on the surface, mainly composed of Ca and P. | [ |
| 316L SS | Hybrid organic-inorganic + wollastonite | – | 5, 33 | SEM, | – | After five days: a Ca-P rich phase was detected in proximity to wollastonite particles. | [ |
| 316L SS | Hybrid organic-inorganic + 45S5 Bioglass | a) Stainless steel; | 30 | SEM, | – | Formation of HA on both test surfaces. | [ |
| Hybrid organic-inorganic + 45S5 Bioglass with Ca partially substituted with 2 mol% of Sr | |||||||
| Mg alloy (AZ91) | Diopside + bredigite + | a) Coated Mg alloy (ASD/AZ91); | 3, 7, 14, 21, 28 | SEM, | ICP | Amount of degradation and precipitates on the surface: composite/ASD/AZ91 > ASD/AZ91 > AZ91. | [ |
| Mg alloy (ZK61) | Dimagnesium silicate + Magnesium oxide + Clinoenstatite | – | 7, 14 | SEM, | – | Quick growing of the apatite layer. | [ |
| Mg alloy (AZ31) | 45S5 glass–ceramic | Uncoated | 1, 7, 14 | SEM, | – | Enhanced corrosion resistance of coated sample over the first seven days. | [ |
| Mg alloy (AZ31) | 45S5 glass–ceramic | Uncoated | 1, 3, 5, 7 | SEM, | _ | Samples with the thickest coating, 3A500, showed lower (2.31%) mass loss than A500 (72.71%), 2A500 (72.24%) and uncoated (78.04%) samples, along with a lower pH variation of m-SBF after seven days. | [ |
ASD = anodic spark deposition; EPMA = electron probe micro-analyzer; HT = hydrothermal treatment; TMS = TEOS (tetraethoxysilane)–MTES (methyltriethoxysilane)–SiO2.
Figure 4Surface evolution of the samples (BGCa3) immersed in SBF for increasing times, from Cattini et al., 2013 [98].
Bioactive coatings: in vitro experiments.
| Substrate | Coating Material | Control | Cells | Test Performed | Main Results | References |
|---|---|---|---|---|---|---|
| CpTi | Sphene | Uncoated | hADSCs | - MTT assay | Sphene-based coating significantly better supported cell attachment and proliferation, than CpTi samples. | [ |
| Ti-6Al-4V | Sphene | Uncoated | Primary human osteoblasts | - SEM analysis | After seven days of culture, cell proliferation rate on hardystonite coatings was higher when compared with those on sphene coatings and Ti-6Al-4V samples (p < 0.05). | [ |
| Hardystonite | ||||||
| Ti-6Al-4V | Sphene | HA-coated | Human osteoblast-like cells | - SEM analysis | - After seven days of culture, significantly higher cell proliferation and ALP activity on sphene coatings than on HA-coated and uncoated substrates were observed (p < 0.05). | [ |
| Ti-6Al-4V | Hardystonite | Uncoated | MC3T3-E1 cells (a mouse calvaria-derived osteoblast-like | - SEM analysis | Hardystonite showed no toxic effect on cells. | [ |
| Ti-6Al-4V | Hardystonite | HA-coated | Canine BMMSCs | - Immunofluorescence | After 14 days of culture, the expression levels for BMP-2, ALP | [ |
| Sr-substituted hardystonite | ||||||
| Ti-6Al-4V | Akermanite | HA-coated | Rabbit BMMSCs | - SEM analysis | After one day, cells on HA coating were similar in appearance to those on akermanite coating, but with fewer minor filopodia. After seven days of culture, more cells were detected on the akermanite coating than on the HA one. | [ |
| Ti-6Al-4V | Bredigite | - HA-coated | Rabbit BMMSCs | - SEM analysis | Cells cultured on bredigite coating for one day presented an elongated morphology and were firmly attached to the surface. After three days of culture, the bredigite coating presented numerous cells on its surface, characterized by a net-like morphology. | [ |
| Ti-6Al-4V | Wollastonite | – | Rat BMMSCs | - MTT assay | Cells seeded on the HT treated coatings presented higher cell viability and proliferation than untreated coatings at all time points (one, four and seven days) (p < 0.05). | [ |
| CpTi | 45S5 Bioglass | Uncoated | Human osteosarcoma cell line MG63 | - MTT assay | After 24 h of culture, cells spread over the coated surface. After seven days, it appeared covered by a cell layer. | [ |
| Ti grade 4 | x CaO·(1 − x)SiO2 bioactive glass (0.0 ≤ x ≤ 0.60) | Uncoated | NIH 3 T3 murine fibroblasts cells | - WST-8 assay | After 24 h of culture, the cells grown on uncoated samples showed lower viability than on all coated samples (p < 0.05). | [ |
| Ti grade 4 | 70S30CxA bioactive glass (in mol%: 70% SiO2 (S), 30% CaO (C), x% Ag2O (A), with 0.08 ≤ x ≤ 0.27 | Uncoated | NIH 3 T3 murine fibroblasts cells | - WST-8 assay | Higher percentage of viable cells on coated samples than on uncoated ones. | [ |
| Mg alloy (AZ91) | Diopside + bredigite + fluoridated HA | (a) Uncoated; | L-929 fibroblast cell line | - MTT assay | Increase in cell viability from two to seven days of culture in all samples. | [ |
| Mg alloy (AZ91) | Diopside | (a) Uncoated; | L-929 fibroblast cell line | - MTT assay | Cell viability of all samples increased with the culture time. | [ |
| Mg alloy (ZK60) | Dimagnesium silicate – Magnesium oxide | Uncoated | Human osteoblast-like cells (MG63) and NIH 3 T3 murine fibroblasts cells | - CellTiter-96 cytotoxicity test | Dimagnesium silicate-magnesium oxide coatings, with or without gallic acid, favored osteoblast-like cell proliferation. | [ |
ALP = alkaline phosphatase; BMMSCs = bone marrow mesenchymal stem cells; BMP = bone morphogenic protein; hADSCs = human adipose-derived stem cells; qRT-PCR = quantitative reverse transcription polymerase chain reaction; rt-PCR = real time polymerase chain reaction.
Figure 5SEM images of cells grown on: (a) sphene-coated CpTi substrate after 21 days of culture in osteogenic differentiation medium; from Elsayed et al., 2018 [37]; (b) bioceramic coating composed of diopside, bredigite, and fluoridated hydroxyapatite deposited on Mg alloy (AZ91) after seven days of culture; modified from Razavi et al., 2018 [66].
Bioactive coatings: in vivo experiments.
| Substrate | Coating Material | Study Model * | Number of Test Implants | Control Implants § | Sacrifice (wks) | Assessments Method | BIC% | Main Results | References |
|---|---|---|---|---|---|---|---|---|---|
| Ti-6Al-4V | Sphene | Merino sheep (femur) | 20 | (a) Uncoated | 6 | - Histological analysis | In cortico-cancellous bone: | In cortico-cancellous bone, significantly higher BIC% in sphene- and HA-coated implants, than in uncoated ones. | [ |
| Ti-6Al-4V | Hardystonite | Beagle dog (femur) | 12 + 12 | (a) Uncoated | 12 | - Sequential fluorescent labeling | Sr-substituted hardystonite 51.20 ± 9.08. | BIC% of Sr-substituted hardystonite-coated implants was higher than those of hardystonite (p < 0.05) and HA (p < 0.01). | [ |
| Sr-substituted hardystonite | |||||||||
| Ti-6Al-4V | Bioactive glass (SrBG) | New Zealand rabbit (femur and tibia) | 54 | HA-coated | 6,12, 24 | - Push-out test | Quantified | No significant differences in BIC% between the two groups at any time point. | [ |
| Ti | HA + Bioactive glass S53P4 | Beagle dog (mandible) | 16 (HABGHigh) | HA-coated | 4, 12 | - Histological analysis | At four weeks: | After four weeks, in HABGHigh group BIC% was lower than in the other groups (p < 0.05). | [ |
| Ti | HA + Bioactive glass S53P4 (HABG) | Saanen goat (iliac crest) | 32 | (a) Uncoated | 4 | - Removal torque testing | Monocortical: | HABG-coated implants showed higher (p < 0.05) BIC% in both monocortical and bicortical implant placements in comparison with uncoated implants. | [ |
| 316L SS | Hybrid organic-inorganic + wollastonite | Hokkaido rat (femur) | Unclear | Uncoated | 8.5 | - Histological analysis | ~60 coated | After 60 days, newly formed bone around coated implants and fibrous tissue around uncoated implants. | [ |
| 316L SS | Hybrid organic-inorganic + wollastonite | Hokkaido rat (femur) | Unclear | – | 8.5 | - Surface analysis (SEM, EDS, AFM) | – | After 60 days, newly formed bone around coated implant, characterized by the presence of osteocyte lacunae and laminar structure. | [ |
| 316L SS | Hybrid organic-inorganic + 45S5 Bioglass | Wistar–Hokkaido rat (femur) | Unclear | Uncoated | 4, 8 | - SEM analysis | – | Thickness of newly formed bone: at eight weeks ~50 μm for all the samples, but at four weeks lower bone thickness around uncoated implants. | [ |
| Hybrid organic-inorganic + 45S5 Bioglass with Ca partially substituted with 2 mol% of Sr | |||||||||
| Mg alloy (AZ91) | Merwinite | Rabbit (femur: greatee trochanter) | 1 | (a) Uncoated | 8 | - Blood tests | – | On two-wks post-op radiographs: uncoated samples showed higher gas formation than PEO-coated ones, while no gas on test samples. | [ |
| Mg alloy (AZ91) | Diopside | Rabbit (femur: greatee trochanter) | Not specified | (a) Uncoated | 8 | - Blood tests | – | No gas formation was clinically observed in any group. | [ |
* sample size (number of animals) into brackets; § number of control implants into brackets; BA%= peri-implant bone area percentage; BIC = bone-implant contact; PEO: plasma electrolytic oxidation; SAXS = angle X-ray scattering; TRAP = tartrate-resistant acid phosphatase.
Figure 6Histological morphology of the interface between the implant and the bone tissue of: (a) sphene-coated Ti-6Al-4V implant after six weeks of healing (Toluidine blue); from Ramaswamy et al., 2009 [137]; (b) stainless steel implant coated with hybrid organic-inorganic bioactive coating containing wollastonite after 60 days of healing (Toluidine blue); from Ballarre et al., 2011 [157]. Im, implant; NB, new bone.